By investigating a large intrapatient matched PBT distant MET breast cancer cohort [2, 17, 25–27], we have shown that (i) PD-1+/LAG-3+ is strongly associated with a “hot” immune phenotype and (ii) differs between METs and PBTs. This evidence concerns the gene PDCD1 and breast carcinoma.